Senti Biosciences Holdings
SNTI
25 hedge funds and large institutions have $7.56M invested in Senti Biosciences Holdings in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
51% more capital invested
Capital invested by funds: $5.02M → $7.56M (+$2.55M)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.13% less ownership
Funds ownership: 2.7% → 2.57% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60K |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$56.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$17K |
| 4 |
Two Sigma Investments
New York
|
+$11.2K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$8.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.34M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$102K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$47.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$10.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$83 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$1.34M | -314,712 | Closed |
|
|
27
TD Asset Management
Toronto,
Ontario, Canada
| – | -$102K | -24,121 | Closed |
|
|
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$47.1K | -11,097 | Closed |
|
|
29
UBS Group
Zurich,
Switzerland
| – | -$83 | -20 | Closed |
|
SNTI Hedge Fund Activity: Q4 2023 in Review
25 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q4 2023, worth a combined $7.56M — up 51% from $5.02M a quarter earlier.
Fund positioning in SNTI was balanced in Q4 2023: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $60K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $1.34M sold.
- 25 institutional investors held Senti Biosciences Holdings (SNTI) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $7.56M of Senti Biosciences Holdings stock for Q4 2023, up 51% quarter-over-quarter.
- 5 funds opened new Senti Biosciences Holdings positions in Q4 2023 and 5 closed out, a net change of 0 holders.
- The largest Senti Biosciences Holdings buyer in Q4 2023 was Vanguard Group, an estimated $60K added.
- The largest Senti Biosciences Holdings seller in Q4 2023 was T. Rowe Price Associates, an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2023.